Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Hepatocellular Carcinoma · Obesity

Hospital Authority

Hospital Authority, Hong Kong

Hospital Authority clinical programs — 80 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website
Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN HQ
1991 Founded
12,669 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN
Founded
1991
Employees
12,669
Programs
322
Drugs
301
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Hospital Authority projects

80 ClinicalTrials.gov programs sponsored by Hospital Authority.

Hospital Authority has 80 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

80 programs

Clinical programs

Page 1 of 2

  1. 12.5mg sunitinib with Cisplatin and Gemcitabine

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 2 small molecule completed

    1 trial

  2. 5% MInoxidil milky lotion

    Hospital Authority, Hong Kong

    Objective (Goal)

    phase 2 small molecule active

    1 trial

  3. 5-Fluorouracil

    Hospital Authority, Hong Kong

    Cancer (Advanced Stage)

    phase 2 small molecule active

    1 trial

  4. AS01 adjuvant (0.5 mL intramuscular)

    Hospital Authority, Hong Kong

    Immune System Responses and Trained Immunity After AS01 Administration

    phase 2 mab active

    1 trial

  5. ASLAN001

    Hospital Authority, Hong Kong

    Advanced/ Metastatic Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  6. AZD9291

    Hospital Authority, Hong Kong

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  7. Allogenic expanded Natural Killer Cells (AlloNK1)

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 mab active

    1 trial

  8. Apatinib

    Hospital Authority, Hong Kong

    Soft Tissue Sarcoma, Adult, Stage II

    phase 2 small molecule active

    1 trial

  9. Arm1

    Hospital Authority, Hong Kong

    Oral Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  10. Art-BTC

    Hospital Authority, Hong Kong

    Biliary Cancer Metastatic

    phase 2 small molecule active

    1 trial

  11. Atorvastatin

    Hospital Authority, Hong Kong

    Vitiligo

    phase 2 small molecule completed

    1 trial

  12. Avatrombopag

    Hospital Authority, Hong Kong

    Chemotherapy-induced Thrombocytopenia

    phase 2 small molecule active

    1 trial

  13. BMMNCs

    Hospital Authority, Hong Kong

    Retinitis Pigmentosa

    phase 2 mab active

    1 trial

  14. BPF-CCRT (run-in)

    Hospital Authority, Hong Kong

    Stage III Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  15. Bovine colostrum

    Hospital Authority, Hong Kong

    Severe Alcoholic Hepatitis in 'Extremis'- Defined by mDF>54

    phase 2 other completed

    1 trial

  16. CART infusion

    Hospital Authority, Hong Kong

    B-cell Lymphoma Refractory

    phase 2 other active

    1 trial

  17. Cholecalciferol

    Hospital Authority, Hong Kong

    Hematologic Neoplasms

    phase 2 small molecule active

    1 trial

  18. Coriolus Versicolor

    Hospital Authority, Hong Kong

    Carcinoma

    phase 2 small molecule terminated

    1 trial

  19. Cutting balloon followed by paclitaxel coated balloon

    Hospital Authority, Hong Kong

    Dialysis Access Malfunction

    phase 2 other completed

    1 trial

  20. Cytarabine

    Hospital Authority, Hong Kong

    AML

    phase 2 small molecule active

    1 trial

  21. DAOIB

    Hospital Authority, Hong Kong

    Long COVID

    phase 2 small molecule active

    1 trial

  22. DRUID AI Program

    Hospital Authority, Hong Kong

    Solid Organ Malignancies

    phase 2 other active

    1 trial

  23. Darovasertib

    Hospital Authority, Hong Kong

    Ocular Melanoma

    phase 2 small molecule completed

    1 trial

  24. Daunorubicin

    Hospital Authority, Hong Kong

    Down Syndrome

    phase 2 small molecule active

    1 trial

  25. Dental stent

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma

    phase 2 other active

    1 trial

  26. Docetaxel

    Hospital Authority, Hong Kong

    Non Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  27. Dostarlimab

    Hospital Authority, Hong Kong

    Female

    phase 2 small molecule active

    1 trial

  28. Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)

    Hospital Authority, Hong Kong

    Benign Prostatic Hyperplasia

    phase 2 small molecule completed

    1 trial

  29. Doxycycline

    Hospital Authority, Hong Kong

    Tuberculosis, Meningeal

    phase 2 small molecule active

    1 trial

  30. Drug: Pembrolizumab

    Hospital Authority, Hong Kong

    Clear-cell Metastatic Renal Cell Carcinoma

    phase 2 other active

    1 trial

  31. Dupilumab

    Hospital Authority, Hong Kong

    Nephrotic Syndrome in Children

    phase 2 mab active

    1 trial

  32. Expanded , Activated NK cells

    Hospital Authority, Hong Kong

    Ewing Sarcoma

    phase 2 mab active

    1 trial

  33. FEMH-95011

    Hospital Authority, Hong Kong

    Stomach Neoplasms

    phase 2 small molecule active

    1 trial

  34. Faropenem

    Hospital Authority, Hong Kong

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  35. Hyperpolarized 13C-Pyruvate injection

    Hospital Authority, Hong Kong

    Gynecologic Cancer

    phase 2 small molecule active

    1 trial

  36. IN10018

    Hospital Authority, Hong Kong

    Cervical Adenocarcinoma

    phase 2 small molecule active

    1 trial

  37. Ivonescimab 20 mg/kg

    Hospital Authority, Hong Kong

    Nasopharyngeal Carcinoma (NPC)

    phase 2 small molecule active

    1 trial

  38. Lenalidomide [Leavdo®]

    Hospital Authority, Hong Kong

    Antibiotics-unresponsive MALT Lymphoma

    phase 2 small molecule active

    1 trial

  39. Liposorber LA-15 System

    Hospital Authority, Hong Kong

    Cholesterol Embolism

    phase 2 other active

    1 trial

  40. MLC901

    Hospital Authority, Hong Kong

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  41. MSC and PRP

    Hospital Authority, Hong Kong

    Type 1 Diabetes Mellitus

    phase 2 mab active

    1 trial

  42. Morphine

    Hospital Authority, Hong Kong

    Respiratory Depression

    phase 2 small molecule active

    1 trial

  43. NK cells

    Hospital Authority, Hong Kong

    Hepatocellular Carcinoma

    phase 2 mab active

    1 trial

  44. Osteosheet(r)

    Hospital Authority, Hong Kong

    Orbital Trauma

    phase 2 other completed

    1 trial

  45. Pemebit

    Hospital Authority, Hong Kong

    Adenocarcinoma

    phase 2 small molecule completed

    1 trial

  46. Placebo

    Hospital Authority, Hong Kong

    STOMACH NEOPLASM

    phase 2 small molecule active

    1 trial

  47. Quadriceps strength training

    Hospital Authority, Hong Kong

    Patellofemoral Pain Syndrome

    phase 2 other active

    1 trial

  48. Radiation: Radiation Therapy；Biological: Personalized tumor peptide vaccine

    Hospital Authority, Hong Kong

    Advanced Tumors

    phase 2 other active

    1 trial

Frequently asked questions

How many clinical projects does Hospital Authority have?

80 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.